Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Hematologic Oncology Update
00:00
The Effect of Anti-Cd20 on Response Rates in Unmutated CLL Patients
The unmutated IgHV patients are starting to maybe drive some of this benefit. We see about 30% complete remission rates very early on with the addition of the anti-CD20. And we actually see peripheral blood MRD much improved in this 30 to 40%. So, is this an effect of deeper remissions? I'm not so sure. But these intermediate higher-risk clones like unmutated CLL seem to be benefiting.
Transcript
Play full episode
